IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery

Inclusion Criteria: * Histologically confirmed adrenocortical carcinoma * Documented unresectable recurrent, unresectable advanced, or metastatic disease * At least 1 lesion that can be accurately measured by RECIST criteria as ≥ 20 mm by conventional radiologic techniques or as ≥ 10 mm by spiral CT scan or MRI * Patients with disease in an irradiated field as the only site of measurable disease allowed provided there has been a clear progression of the lesion * No tumors potentially resectable by surgical excision alone * No known or suspected leptomeningeal disease or brain metastases * ECOG performance status 0-2 * Life expectancy ≥ 12 weeks * ANC ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 9 g/dL (transfusion allowed) * Serum creatinine ≤ 1.5 times upper limit of normal (ULN) OR calculated creatinine clearance ≥ 60 mL/min * AST or ALT ≤ 3 times ULN * Total bilirubin ≤ 1.5 times ULN * HbA1c \< 8 within the past 4 weeks * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after completion of study therapy * Able to take oral medications * No poor gastrointestinal absorption * Patients with diabetes mellitus are eligible provided they meet all of the following criteria: * Blood glucose is normal (random glucose ≤ 150 mg/dL) * HgbA1c ≤ 8 within the past 4 weeks * On a stable dietary or therapeutic regimen for the past 2 months * No active uncontrolled infection * No seve…